Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Police search for driver who fatally struck a pedestrian in a hit-and-run incident in Chicago's Gage Park neighborhood.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Police search for driver who fatally struck a pedestrian in a hit-and-run incident in Chicago's Gage Park neighborhood.